Malignt melanom är den snabbast ökande cancerformen i Sverige. – Inte minst vi bleka nordbor måste ha sund respekt för solen och vara uppmärksamma på hudförändringar, säger Elisabet Lundborg på Amgen. Under maj, Melanoma Awareness Month, uppmärksammas melanom globalt. I Sverige har vi Melanomveckan då flera hudmottagningar erbjuder tider utan remiss för den som vill kolla sina prickar.
Pivotal Trial Showed IMLYGIC Significantly Increased Durable Response Rates in Patients With Unresectable Melanoma That is Regionally or Distantly Metastatic IMLYGIC is Approved in the European Union Specifically for Early Stage Metastatic Patients
IMLYGIC is First Oncolytic Immunotherapy to Demonstrate Therapeutic Benefit for Patients With Advanced Melanoma.
Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.se
Gustav III:s Boulevard 54
169 27 Solna
Sverige